Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor

A. Craig Lockhart, Rod D. Braun, Daohai Yu, Joel R. Ross, Mark W. Dewhirst, Jeffrey S. Humphrey, Seth Thompson, Kathleen M. Williams, Bruce Klitzman, Fan Yuan, James M. Grichnik, Alan D. Proia, Delina A. Conway, Herbert I. Hurwitz

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Purpose: The purpose of this study was to evaluate the feasibility of incorporating a novel wound angiogenesis assay into a Phase I study of BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor, and to determine whether the wound angiogenesis assay was able to detect the inhibition of angiogenesis in patients treated with BMS-275291. Experimental Design: Before treatment began, a 4-mm skin biopsy was performed. The wound was imaged for 14 days. Treatment was started on day 0, and a separate 4-mm biopsy was performed 14 days later. The second wound was also imaged for 14 days. Wound angiogenesis was scored by two independent observers who were blinded to treatment status. Results: The median times in days (95% confidence interval) to reach the target average vascular score (AVS) of 1.5 and 2.0 based on the data of Observer 1 were 3.7 (2.2-6.9) and 8.0 (5.0-10.0) pretreatment whereas on-treatment the values were 4.9 (3.7-8.0) and 9.3 (7.0-11.5), respectively. The delay in the median time to reach an AVS of 1.5 was 1.2 days or a 32% reduction when comparing pretreatment with on-treatment (P = 0.06). For the target AVS of 2.0 the delay in the median time pretreatment versus on-treatment was 1.3 days or a 16% reduction (P = 0.04). Conclusions: The wound angiogenesis assay used in this study was practical, well tolerated, and reproducible. Delays in wound angiogenesis because of BMS-275291 were detectable with this assay. This technique warrants additional investigation in clinical trials of other antiangiogenic agents.

Original languageEnglish (US)
Pages (from-to)586-593
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number2
StatePublished - Feb 1 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor'. Together they form a unique fingerprint.

  • Cite this

    Lockhart, A. C., Braun, R. D., Yu, D., Ross, J. R., Dewhirst, M. W., Humphrey, J. S., Thompson, S., Williams, K. M., Klitzman, B., Yuan, F., Grichnik, J. M., Proia, A. D., Conway, D. A., & Hurwitz, H. I. (2003). Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clinical Cancer Research, 9(2), 586-593.